News Article

Columbia Grants Health Fidelity Exclusive License to MedLEE NLP-- Clinical Natural Language Processing to improve usability of health information
Date: Jan 11, 2012
Source: Fierce Biotech ( click here to go to the source)

Featured firm in this article: Health Fidelity Inc of San Mateo, CA

NEW YORK & MENLO PARK, Calif.--(BUSINESS WIRE)-- Columbia University and Health Fidelity, Inc. announced today that they have entered into a license agreement for commercialization of Columbia's MedLEE Natural Language Processing technology. The license grants Health Fidelity exclusive rights to a portfolio of patents, software code, and trademarks for commercialization of MedLEE-related products and services dedicated to improving healthcare.

"We're delighted to be commercializing MedLEE, one of the most reliable and heavily used clinical natural language processing (NLP) engines," said Dan Riskin, CEO of Health Fidelity. "Through natural language processing technology, Health Fidelity enables medical practitioners and administrators to effectively make use of the wealth of information they collect so they can make better medical decisions, monitor and improve quality of care, and enable R&D that will bring us to the next frontier in healthcare. Our Fidelity Platform incorporates this technology and provides a robust, high quality, cloud-based clinical NLP platform that easily integrates with and improves the capabilities of our solution partners' applications."

Clinical NLP supports automated extraction of discrete medical information, critical to meeting goals in Meaningful Use, accountable care organizations (ACO), and ICD 10 conversion. Through two decades of development and improvement, MedLEE (Medical Language Extracting and Encoding) has the most associated peer reviewed publications of any clinical NLP engine and is associated with many of the earliest patents in the space.

Dr. Carol Friedman, inventor of MedLEE and Professor and Vice Chair of the Department of Biomedical Informatics at Columbia University Medical Center, will serve on Health Fidelity's advisory board, where she will support the transfer and integration of the technology into Health Fidelity's platform products. "We chose to partner with Health Fidelity because of the qualifications of its team, its substantial experience with MedLEE, and its vision for natural language processing as essential technology to empower and advance healthcare," said Dr. Friedman.

"It was very important for us to select a partner with broad as well as deep understanding of the transformative potential of natural language processing in the medical and clinical domains," said Donna See, Director of Strategic Initiatives at Columbia Technology Ventures, the technology transfer office of Columbia University. "This is an exciting opportunity that we hope will pave the path for a new era of data-driven healthcare."

About Health Fidelity

Health Fidelity, Inc. offers a clinical natural language processing (NLP) platform that enables medical practitioners and administrators to effectively make use of the wealth of currently unusable medical information they collect. The company works with solutions partners to provide end-user applications built on the robust clinical data our powerful platform extracts. As a result, end-users can make better medical decisions, monitor and improve the quality of care, and enable R&D that will bring us to the next frontier in healthcare. For more information on Health Fidelity, please visit

About Columbia Technology Ventures

A leading academic and research university, Columbia University continually seeks to advance the frontiers of knowledge and to foster a campus community deeply engaged in understanding and addressing the complex global issues of our time. Columbia University's technology transfer office, Columbia Technology Ventures, manages Columbia's intellectual property portfolio and serves as the university's gateway for companies and entrepreneurs seeking novel technology solutions. Our core mission is to facilitate the transfer of inventions from academic research to outside organizations for the benefit of society on a local, national and global basis. For more information on Columbia Technology Ventures, please visit